度洛西汀联合米氮平治疗难治性抑郁症的临床观察

Observation on the Efficacy of Duloxetine Combined with Mirtazapine in the Treatment of Refractory Depression

目的探讨度洛西汀联合米氮平治疗难治性抑郁症患者的疗效。方法 30例难治性抑郁症患者给予度洛西汀联合米氮平治疗,疗程8周。分别评定治疗前及治疗1、2、4、6和8周应用汉密尔顿抑郁量表(HAMD)和治疗中出现的症状量表(TESS)疗效与不良反应。结果治疗4周,HAMD评分从治疗前(24.49+5.16)分降至(18.22+4.23)分(t=5.16,P<0.01);治疗8周,HAMD评分降至(12.37+4.85)分(t=9.37,P<0.01)。TESS评分显示不良反应发生率低,程度轻。结论度洛西汀联合米氮平治疗难治性抑郁症安全有效。

Objective To explore the curative effect of duloxetine combined with mirtazapine in the treatment of refractory depression.Methods 30 cases of patients with refractory depression were treated with venlanfaxine and mirtazapine for 8 weeks.Hamilton depression rating scale（HAMD）and treatment emergent symptom scale（TESS）were used to assess the curative effect and adverse reactions before the treatment,and 1,2,4,6,8 weeks after the treatment, respectively.Results HAMD scores changed from 24.49＋5.16 at pretreatment to（18.22±4.23）at the fourth week of treatment（t=5.16,P〈0.01）,to 12.37±4.85 at the eighth week of treatment（t=9.37,P〈0.01）.TESS evaluation showed a low incidence of adverse reactions.Conclusion Duloxetine combined with mirtazapine is safe and effective in the treatment of patients with refractory depression.